as an adjuvant. Minor detrimental effects were, however, observed in the ensuing CD8 + T cell responses suggesting that the use of d-amino acids affects antigen processing and presentation pathways involved in generation of cellmediated immunity at least when facilitated through TLR2. Both d-and l-forms were found to be resistant to digestion by trypsin, indicating resistance of the branched structure to protease activity.
Introduction
Adjuvants are often administered with antigen to improve the quality and magnitude of ensuing immune responses. Alum, which has been used in human vaccines for more than 80 years, is appropriate for those vaccines where clearance of pathogens depends on the induction of antibody responses (Pasquale et al. 2015) . Alum is not, however, known for its ability to elicit and maintain cell-mediated CD8 + T cell responses (Knudsen et al. 2016) .
Vaccine delivery approaches using agonists of Toll-like receptors (TLRs) offer an advantage over alum, because they facilitate delivery of antigens to dendritic cells (DCs) improving antigen uptake leading to cell maturation which results in the production of pro-inflammatory cytokines that can lead to induction of antibody as well as cell-mediated immunity (CMI) particularly CD8 + T cell responses (Kastenmüller et al. 2011; Pufnock et al. 2011; Chua et al. 2011 Chua et al. , 2015 Goff et al. 2015) . The induction of CMI is particularly important in providing protection against intracellular pathogens (Elemans et al. 2012 ).
Abstract
The lipopeptide, R 4 Pam 2 Cys, associates electrostatically with soluble protein antigens and significantly enhances their ability to induce protective humoral and cell-mediated responses. We demonstrate that antibody titers elicited by the antigen ovalbumin (OVA) associated with R 4 Pam 2 Cys are higher than those elicited by OVA in the presence of alum and comparable to those elicited by OVA formulated with complete Freund's adjuvant (CFA). The hierarchy of anti-OVA antibody avidities was CFA > R 4 Pam 2 Cys = alum. Each of the three adjuvants facilitated IgG class-switching with significantly more IgG1 elicited by OVA when formulated with R 4 Pam 2 Cys. The effects of substituting naturally occurring l-stereoisomers of the cationic residues within R 4 Pam 2 Cys with d-stereoisomers revealed that substitution did not affect the ability of R 4 Pam 2 Cys to stimulate dendritic cell maturation or its ability to elicit antibody production when used 1 3
Our laboratory has developed a lipopeptide-based vaccine delivery system containing the TLR2 agonist S- [2,3-bis(palmitoyloxy) propyl] cysteine (Pam 2 Cys). A feature of this lipopeptide, R 4 Pam 2 Cys (Fig. 1a) , is its branched structure based on a scaffold of lysine residues with N-terminal arginine residues which impart an overall positive charge. This structure allows electrostatic association with oppositely charged regions of protein antigens under physiological conditions (Chua et al. 2011) . The non-covalent association between antigen and R 4 Pam 2 Cys overcomes the complexities associated with covalent conjugation of antigen and adjuvant. Formulation of antigens with R 4 Pam 2 Cys enhances their immunogenicity (Chua et al. 2011 (Chua et al. , 2012 (Chua et al. , 2015 and is more effective at inducing CD8 + T cell responses when compared to other adjuvants (Chua et al. 2014) .
Our previously reported (Chua et al. 2011 ) method of synthesis of R 4 Pam 2 Cys was to couple Fmoc-Lys(Mtt)-OH to the solid support which allowed the branched lysinebased structure to be assembled from the α-amino group exposed following removal of the Fmoc protecting group (Fig. 1b, Method 1) . Attachment of Pam 2 Cys then takes place following removal of the Mtt group from the ε-amino group of the C-terminal lysine. While this method is effective, there remains a possibility that steric hindrance posed by the branched lysine structure may limit assembly of the The molecule is assembled as a two-tiered branching scaffold composed of lysine (K) residues to which are attached arginine (R) residues. The lipopeptide contains the TLR2 agonist Pam 2 Cys which is attached to one of the two serine residues (S 2 ) coupled to the ε-amino group of the C-terminal K residue. b R 4 Pam 2 Cys was synthesized using solidphase peptide synthesis methodologies using two different synthetic routes. Method 1 (left); Fmoc-Lys(Mtt)-OH was coupled to the solid support (grey sphere) which allows assembly of the branched lysine structure at the α-amino group of the C-terminal K residue following removal of the Fmoc group. Arginine residues are then ligated to the ε and α-amino groups of the N-terminal K residues. The moiety is then assembled at the exposed ε-amino group of the C-terminal K residue following removal of the Mtt protecting group. Method 2 (right); Dde-Lys(Fmoc)-OH is attached to the solid support followed by removal of the Fmoc group and assembly of the Pam 2 Cys moiety at the exposed ε-amino group of the C-terminal K residue. Removal of the Dde group then allows assembly of the branched lysine structure at the N-terminal α-amino group of the C-terminal K residue as described in Method 1 Pam 2 Cys moiety. We reasoned that improved yields may be attained if Pam 2 Cys is assembled before the branched structure. We therefore used Dde-Lys(Fmoc)-OH in the C-terminal position which allows attachment of the lipid at the ε-amino group before beginning assembly of the branched structure at the α-amino group (Fig. 1b, Method  2) . We then compared the quality and yield of R 4 Pam 2 Cys synthesized using Method 1 and Method 2 as well as investigated the biological activities of the products by examining their abilities to induce antibody and cell-mediated responses when formulated with the model antigen, ovalbumin (OVA).
The use of synthetic peptides in clinical applications can be hampered by short biological half-lives due to their susceptibility to in vivo enzymatic degradation by proteases (Galati et al. 2003) . Peptides composed of d-amino acids are, however, more protease-resistant while retaining biological activity (Hamamoto et al. 2002; Tugyi et al. 2005) . We therefore examined the effects of substituting l-stereoisomers of component amino acids with the corresponding d-stereoisomers and evaluated if these alterations affected the susceptibility of R 4 Pam 2 Cys to protease-mediated hydrolysis as well as its ability to elicit antibody and CD8 + T cell responses.
Materials and methods

Synthesis of R 4 Pam 2 Cys
Schematics summarizing the strategies employed for the assembly of R 4 Pam 2 Cys are shown in Fig. 1b , Method 1 and 2.
In Method 1, Fmoc-Lys(Mtt)-OH (Novabiochem, Hohenbrunn, Germany) was coupled to the solid support, PEG-SRAM (Rapp Polymere, Tübingen; Germany, substitution factor 0.24 mmol/g), in fourfold molar excess in the presence of equimolar amounts of O-benzotriazole-N,N,Nʹ,Nʹ-tetramethyl-uronium-hexa-fluoro-phosphate (HBTU; Protein technology, Inc, USA), 1-hydroxybenzotriazole (HOBt; CEM, USA), and a sixfold molar excess of diisopropylethylamine (DIPEA; Sigma, Castle Hill, Australia) for 45 min. The conditions for this acylation step were also used for the coupling of other amino acid residues in this study or otherwise stated specifically. The α-amino group of this C-terminal lysine was then exposed following removal of the Fmoc group using 2.5% 1,8-diazobicyclo(5.4.0)undec-7-ene (DBU; Sigma-Aldrich, Missouri, USA) in N,N-dimethylformamide (DMF; Merck, New Jersey, USA) for 10 min and a second lysine residue added using Fmoc-Lys(Fmoc)-OH (Novabiochem, Hohenbrunn, Germany). Removal of Fmoc protecting groups at the α-and ε-amino groups of the second lysine using DBU then allowed a tier of 2 lysine residues to be added again using Fmoc-Lys(Fmoc)-OH. Following removal of the 4 Fmoc protecting groups using DBU and exposure of the 4 amino groups, Fmoc-Arg(Pbf)-OH (Novabiochem, Hohenbrunn, Germany) was then added to terminate the branched peptide structure with arginine residues. Following removal of the N-terminal Fmoc groups, the primary amino groups of the N-terminal arginine residues were protected by acylation with a tenfold molar excess of di-tert-butyl dicarbonate (FlukaChemika, Buchs, Switzerland) in the presence of DIPEA. This step was necessary to prevent acylation of the α-amino groups present on the arginine residues during the subsequent lipidation process.
Removal of the Mtt protective group attached to the ε-amino group of the C-terminal lysine was achieved by continual washing with 1% trifluoroacetic acid (TFA; Auspep, Parkville, Australia) in dichloromethane (DCM; Chem-supply, Adelaide, Australia) every 5 min over a period of 1 h. Two serine residues, Fmoc-Ser(tBU)-OH (Novabiochem, Hohenbrunn, Germany), were then serially coupled to the exposed ε-amino group and Fmoc-Cys-diol (manufactured according to Wiesmüller et al. (1983) and modified by Zeng et al. (Zeng et al. 1996) ) was coupled to the terminal serine residue in a fourfold molar excess with HOBt together with a sixfold molar excess of DICI dissolved in DCM. A tenfold molar excess of palmitic acid (Acros Organics, New Jersey, USA), an equimolar amount of DMAP (Fluka, Steinheim, Germany) and a 12-fold molar excess of DICI in DCM was then added and the reaction allowed to proceed overnight at room temperature. The solid support was then washed with DCM and a final deprotection step performed to remove the remaining Fmoc group from the cysteine residue.
Cleavage of the final product from the solid support was achieved by incubating the resin with 88% TFA, 5% phenol (Merck, New Jersey, USA), 2% triisopropylsilane (TIIPS; Merck, New Jersey, USA) and 5% water for 3 h at room temperature (Chua et al. 2011) . Lipopeptides were then purified using reverse-phase (RP) HPLC with a Vydac C4 column (6 × 250 mm) installed in a Shimadzu HPLC chromatography system (California, USA) at a flow rate of 2.5 mL/min using 0.1% TFA in water and 0.1% TFA in acetonitrile (VWR Chemicals, Philadelphia, USA) as the limit solvent.
In Method 2, Dde-Lys(Fmoc)-OH (Novabiochem, Hohenbrunn, Germany) was coupled to the solid support as the first amino acid. Following removal of the Fmoc protective group from the ε-amino group, the serine residues and Pam 2 Cys lipid moiety were coupled as described above. The Dde protective group on the α-amino group of the C-terminal lysine was then removed by washing with 2% hydrazine hydrate (Fisons AAG, NSW, Australia) in DMF every 5 min for 10 min (Bycroft et al. 1993; Zeng et al. 2011 ) and the branched lysine structure assembled as described in Method 1.
Synthesis of R 4 Pam 2 Cys containing d-isomers
Synthesis of R 4 Pam 2 Cys containing d-isomers of lysine and arginine was performed using Method 2 except that Fmocd-Lys(Fmoc)-OH (P3 BioSystems, Louisville, USA) and Fmoc-d-Arg(Pbf)-OH (P3 BioSystems, Louisville, USA) were used to assemble the branched structure.
Characterization of lipopeptides
The purity of each product was analyzed by reversed-phase high-performance liquid chromatography (RP-HPLC) using a Vydac Protein C4 column (4.6 mm × 250 mm) installed in a Shimadzu HPLC chromatography system using a flow rate of 1 mL/min and 0.1% trifluoroacetic acid (TFA) in H 2 O and 0.1% TFA in acetonitrile as the limit solvent. Peptide content was determined by amino acid analysis using Waters AccQTag derivatization reagents according to the manufacturer's instructions and analysis using a Waters Acquity UPLC System using an AccQTag ultra column (2.1 × 100 mm). The mass of each lipopeptide was determined using an Agilent 1100 Series LCM/MSD Ion Trap mass spectrometer.
The recoveries of R 4 Pam 2 Cys synthesized using Method 1 or Method 2, are expressed as a percentage of the total theoretical yield (Y) determined using the formula:
where (R 4 Pam 2 Cys)mg is the yield in mg of R 4 Pam 2 Cys (determined by amino acid analysis); S is the weight of solid support used for the synthesis; s is the substitution factor of the solid support and Mr, the molecular weight of R 4 Pam 2 Cys.
Lipopeptide-antigen binding assay
10 µg of ovalbumin (OVA, 0.22 nmol; InvivoGen, California, USA) was mixed with a threefold molar excess of R 4 Pam 2 Cys synthesized by Method 1 or Method 2 in a total volume of 50 µL of saline in a microtube. The size distribution and polydispersity of particles were measured in a 4-μL disposable cyclic olefin co-polymer cuvette installed in a DynaPro NanoStar dynamic light scattering (DLS) instrument (Wyatt Technology, Santa Barbara, USA). The size of particles is reported as radius in nm and percent polydispersity as the ratio (base-line width of size distribution/mean size distribution) in solutions. N.B. Solutions with particles that are >30% poly-dispersed can be
considered to be heterogeneous in their size distribution (Geers et al. 2016 ).
Up-regulation of surface MHC class II expression on D1 cells
Immature murine dendritic, D1 cells, were cultured from C57BL/6 mice as previously described (Chua et al. 2008) . After 21 days of culture, D1 cells were shown to display surface MHC class II and CD11c expression by staining with FITC-conjugated anti-murine I-A/I-E and PE-conjugated CD11c antibodies (both from Biolegend, San Diego, USA), respectively, for 30 min at 4 °C. Cells (2 × 10 5 ) were incubated with 0.02, 0.2, or 2 ng (0.44, 4.4, or 44 fmol) of OVA pre-mixed with a threefold molar excess of lipopeptide in a total volume of 500 µL of D1 media (Chua et al. 2008 ) in a 48-well plate. Cells were also incubated with 0.02, 0.2, or 2 ng OVA alone or maintained untreated. After an incubation period of 14 h, cells were stained with anti-I-A/I-E-FITC. Samples were analyzed by flow cytometry using a FACSCalibur (BD Biosciences, USA) and data analyzed using FlowJo software (Tree star, Inc, USA).
Intracellular cytokine staining (ICS) assay
For measurement of antigen-specific cell-mediated immune responses following inoculation with OVA, 6-to 8-weekold C57BL/6 mice (4 mice per group) were inoculated via the subcutaneous (s.c.) route at the base of the tail with 25 µg (0.55 nmol) of OVA alone or OVA formulated with a threefold molar excess of R 4 Pam 2 Cys in a total volume of 100 µl of saline. The spleens of vaccinated animals were removed 7 days after inoculation and cell suspensions incubated with the H-2K b restricted, OVA-derived peptide epitope SIINFEKL (OVA [257] [258] [259] [260] [261] [262] [263] [264] ; 1 mg/mL) in RPMI-1640 medium (Invitrogen, USA) supplemented with 10% heat-inactivated fetal calf serum (FCS), gentamicin (12 mg/mL), 2 mM glutamine, 1 mM sodium pyruvate, penicillin (100 IU/mL), streptomycin (100 mg/mL) and 55 mM 2-mercaptoethanol, Brefeldin A (1 mg/mL) in the form of BD GolgiPlug from the Cytofix/Cytoperm Plus Kit (Becton-Dickinson) and recombinant IL-2 (10 U/mL; Roche, Mannheim, Germany) at 37 °C and 5% CO 2 . After 11 h, lymphocytes were washed with FACS Wash Buffer (1% FCS 5 mM EDTA in PBS) and stained with a PerCPconjugated rat anti-mouse CD8 antibody (Clone 53-6.7; Becton-Dickinson). Fixation and permeabilization of cell membranes was then performed for 20 min at 4 °C using Cytofix/Cytoperm solution (Cytofix/Cytoperm Plus Kit, Becton-Dickinson) according to the manufacturer's instructions. Cells were washed once and stained with a FITCconjugated rat anti-mouse IFN-γ antibody (CloneXMG1.2; Becton-Dickinson) before flow cytometric analysis using a FACs Canto II (BD Biosciences, USA). Data analysis was performed using FlowJo software (Treestar, Ashland, OR).
Measurement of antigen-specific antibody responses
Groups of female 6-to 8-week-old BALB/c (4-5 mice per group) were inoculated by the s.c. route at base of tail on day 0 and again on day 21 with 25 µg of OVA alone or OVA formulated with a threefold molar excess of lipopeptide in a total volume of 100 µL of saline. Sera were obtained from blood taken 3 weeks after the primary inoculation and also 2 weeks after the secondary inoculation. Flat-bottom-well polyvinyl plates (96 wells/plate) were coated with OVA antigen (5 µg/mL) in PBS for 18-20 h at room temperature in a humidified atmosphere. Unbound antigen was discarded and bovine serum albumin (BSA) (10 mg/mL) in PBS was added as a blocking solution for 1 h before washing with PBS containing v/v 0.05% Tween-20. Serial dilutions of sera obtained from immunized mice were added to wells and held overnight at room temperature. After washing, antigen-bound antibody was detected using horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG antibodies (Dako Agilent Pathology Solutions, Denmark) or anti-rat mouse isotype-specific antibodies (SouthernBiotech, Birmingham, USA) for 1 h. The enzyme-substrate (0.2 mM 2,29-azino-bis 3-ethylbenzthiazoline-sulfonic acid in 50 mM citric acid containing 0.004% hydrogen peroxide) was then added and left to develop for 15 min before addition of 50 mM sodium fluoride (NaF; 50 µL/well) to stop the reaction. Antibody titers were expressed as the reciprocal of the highest dilution of serum required to achieve an OD of 0.2.
Analysis of antisera-antigen binding
Analysis of antisera-antigen binding was performed by surface plasmon resonance using a Bio-Rad ProteOn (Hercules, CA). OVA was diluted in 10 mM sodium acetate (pH 4.5) and immobilized on the solid phase of a GLC Sensorchip (Bio-Rad) flow cell using standard amine coupling chemistry as described by the manufacturer. An adjacent flow cell, to which protein was not introduced, was activated and quenched in the same manner to serve as a negative control. Mouse sera were diluted 1:10 in running buffer (PBS with 3 mM EDTA and 0.05% Tween 20). All experiments were performed at 25 °C using a flow rate of 30 μμL/min running buffer with an injection time of 120 s and dissociation time of 600 s. The data were collected as described by Real-Fernandez et al. (2015) . The surface was regenerated using glycine-hcl (pH 2.5). Binding levels of antibody were expressed as the mean of the maximum response (R max ) attained.
Tryptic digestion
R 4 Pam 2 Cys (15 μg) containing l-or d-isomers of lysine and arginine were pre-treated with trypsin versene (60 μg, Department Microbiology and Immunology, University of Melbourne) in a final volume of 150 μL for 10 min at 37 °C. The mixtures were centrifuged at 13,000 rpm for 1 min and 100 μL of each supernatant analyzed by RP-HPLC using a Vydac C4 column (4.6 mm × 250 mm) installed in a Shimadzu HPLC system as described above. Eluting material was detected by measuring the optical absorbance at 214 nm. As a positive control for the activity of trypsin, Pam 2 CysSK 4 (synthesized in-house) was pretreated with trypsin in a similar manner.
Statistical analysis
Analysis of variance and p values were determined using one-way analysis of variance (ANOVA) non-parametric test and Tukey's multiple comparison test performed using the Prism 6 software package (Graphad Software, La Jolla, CA, USA).
Results
Antigen binding properties of R 4 Pam 2 Cys synthesized using Method 1 or Method 2 R 4 Pam 2 Cys assembled by Methods 1 and 2 and analyzed by HPLC each revealed a single major species (Fig. 2a ) which each exhibiting a mass similar to the expected value (Fig. 2b) .
Comparison of yields from three batches synthesized by each method demonstrated that Method 2 provided an almost twofold average improvement in recovery of product compared with Method 1 (Fig. 2c) . Furthermore, more consistent quantities were recovered using Method 2.
We have previously shown (Chua et al. 2011 ) that OVA, which has a net negative charge of −11, forms complexes when mixed with R 4 Pam 2 Cys. To investigate whether the different methods of assembling R 4 Pam 2 Cys affects its ability to bind to OVA, we analyzed the sizes of particles formed after mixing lipopeptide and antigen by dynamic light scattering (DLS). The results (Fig. 3) show that solutions containing OVA alone or lipopeptide alone contain heterogeneously sized particles with dominant populations exhibiting average radii <20 nm. Association of OVA and R 4 Pam 2 Cys synthesized using Method 1 or Method 2 yielded larger, similarly sized complexes with the majority being ~350 to 380 nm in radius. The percentage polydispersity of complexes formed between OVA and either lipopeptide were within the range (<30%) that would be considered mono-dispersed and indicative of uniform size. This is in contrast to the broader distribution of particle sizes present in solutions containing either OVA or the individual lipopeptides alone.
Antibody and CD8
+ T cell responses induced by antigen formulated with R 4 Pam 2 Cys synthesized by Method 1 or Method 2
We evaluated antibody and CD8 + T cell responses induced by antigen formulated with R 4 Pam 2 Cys in BALB/c and C57BL/6, respectively. Our justification for using these two strains is based on many studies reporting differences in their immune response bias. BALB/c mice are widely known to induce better Th2-type bias and hence are more suitable for inducing and studying antibody responses, whereas C57BL/6 mice are better at inducing a Th1-type bias and thus CD8 + T cell responses (Heinzel et al. 1989; Chen et al. 2005; Mourglia-Ettlin et al. 2016) . The use of each strain therefore provides the best measure of the type of immune response examined. C57BL/6 mice were inoculated with OVA alone or OVA formulated with R 4 Pam 2 Cys assembled by Method 1 or Method 2 and CD8 + T cell responses in the spleen measured 7 days later using an ICS assay. The results show that inoculation of mice with OVA formulated with either lipopeptide induced higher levels of CD8 + T cells secreting IFN-γ than did OVA alone (Fig. 4a) . No differences in responses were observed with either one or the other forms of R 4 Pam 2 Cys used indicating that the different methods of synthesis do not affect the lipopeptides abilities to induce CD8 + T cell responses. Low antibody titers were detected in all BALB/c mice receiving a single dose of antigen (Fig. 4b ), but after two doses, much higher titers of antibody were present in mice that received OVA formulated with R 4 Pam 2 Cys synthesized by Method 1 or Method 2 than mice inoculated with OVA alone. Again, no significant differences in antibody titers were detected between animals vaccinated with R 4 Pam 2 Cys synthesized using Method 1 or Method 2. We conclude that Method 2 improves yield without impacting biological activity of the product.
Comparison of antibody responses induced by OVA formulated with R 4 Pam 2 Cys M2, alum and CFA
Formulation of OVA with R 4 Pam 2 Cys M2 elicits a secondary antibody response with significantly higher antibody titers than OVA formulated with alum and titers which are comparable to antibody titers obtained with a single dose of OVA formulated with complete Freund's adjuvant (Fig. 5a) .
IgG1 was the dominant antibody isotype elicited by OVA formulated with each of the adjuvants, but no IgG1 was detected when OVA was inoculated in the absence of adjuvant (Fig. 5b) . The titers of IgG1 isotype induced by R 4 Pam 2 Cys M2 were higher than those induced by CFA or alum. In addition, IgM was present in sera of mice vaccinated with all formulations with the highest titer detected in mice inoculated with the CFA-OVA combination. The avidities of binding between antibodies and OVA, measured by surface plasmon resonance (Fig. 5c ) demonstrated that there was little or no interaction between OVA and sera obtained from animals inoculated with OVA alone. In the case of sera from animals vaccinated with OVA formulated with R 4 Pam 2 Cys M2, alum or CFA, however, resonance signals indicative of association of serum antibodies with antigen were detected. A comparison of R max values indicate that antibodies obtained from animals inoculated with OVA in the presence of CFA exhibited the strongest avidity, while antibodies obtained from animals inoculated with OVA and alum or OVA and R 4 Pam 2 Cys synthesized by Method 2 had similar avidity (Fig. 5d) . l-stereoisomers to avoid lack of recognition by and signaling through TLR2.
Association of R
The results (Fig. 6a ) of the experiments demonstrate that the sizes of each lipopeptide stereoisomer are similar with perhaps a slight skewing of size and size distribution of R 4 Pam 2 Cys D to the right (Fig. 5a) . Nevertheless, the average sizes of each stereoisomer were similar (Fig. 6b) .
Because of the key role played by DCs in inducing immune responses, we compared the effectiveness of lipopeptides to stimulate DC maturation by determining the expression of surface MHC class II following incubation of spleen-derived D1 cells with R 4 Pam 2 Cys or R 4 Pam 2 Cys D -OVA complexes. At none of the concentrations tested was OVA alone able to induce significant up-regulation of MHC class II expression (Fig. 7a) , whereas formulation of OVA with either R 4 Pam 2 Cys or R 4 Pam 2 Cys D was able to activate these cells with similar efficiency confirming that the in vitro biological activity of R 4 Pam 2 Cys is independent of the stereochemistry of the lysine and arginine residues present in the branched structure. + T cell response were compared (Fig. 7b) (Fig. 7c) . + T cells elicited by the various treatments. b Groups of BALB/c mice (n = 5 per group) were inoculated on day 0 and again on day 21 with the same inocula as indicated above. Sera were obtained from blood taken 20 days after the primary (1°) and 14 days after the secondary inoculations (2°). Antibody responses were then determined by ELISA. The antibody titers of individual animals are presented with the mean value shown as the horizontal bar. *p < 0.01 as determined by one-way ANOVA hydrolyses peptide bonds at the carboxyl side of arginine and lysine unless followed by proline (Simpson 2006) .
Antibody and CD8
We confirmed the activity of trypsin by incubation with the Pam 2 Cys agonist, Pam 2 CysSK 4 , which contains L-isomeric forms of lysine residues arranged in linear sequence. Analysis by RP-HPLC (Fig. 8a ) demonstrated that Pam 2 CysSK 4 presents as a single major peak which elutes at 40 min, whereas the trypsin preparation used presented two major peaks eluting at approximately 22 and 32 min. Exposure of Pam 2 CysSK 4 to trypsin resulted in significant reduction in the size of the major peak and the appearance of 4 smaller peaks with retention times clustered around 40 min. Analysis of the components under these peaks by mass spectrometry revealed species with masses corresponding to intact Pam 2 CysSK 4 and truncated forms with losses of 1-2 lysine residues (data not shown). These results indicate that the trypsin used is effective at degrading a Pam 2 Cys-based lipopeptide containing l-amino acids.
In degradation as indicated by the similarities of the HPLC chromatogram profiles obtained before and after exposure to trypsin (Fig. 8b) . These results indicate that irrespective of isomer, the branched arrangement of lysine and arginine residues within R 4 Pam 2 Cys confers resistance to proteolytic digestion.
Discussion
We have shown that the manufacture of R 4 Pam 2 Cys can be improved, without affecting its ability to enhance immunogenicity of antigens with which it is formulated, simply by reversing the order in which Pam 2 Cys and the branched moiety are assembled into the product. Addition of the lipid moiety prior to addition of the branched structure provided a more consistent record of manufacture than when the lipid moiety is added after the branched structure has been put in place. Although there was little statistical significance in the yields produced by the two methods, which could be attributed to the variability observed using Method 1, the trend for higher and more consistent yields was apparent using Method 2. If it is assumed that the coupling efficiency at each acylation cycle is ~90%, it becomes apparent that the overall yield for coupling 10 amino acids, 1 Cys-diol, and 2 palmitic acid residues will be ~25%. D at a threefold molar excess in a total volume of 50 µl of saline were analyzed for their dynamic light scattering properties. Formed particle size distributions within these solutions are presented as the radius in nm with the average particle size of populations within each histogram indicated as is the percentage polydispersity (Pd). b Average size data representative of triplicate samples: mean particle size (±SD) Therefore, an improvement of 2-4% in addition to the consistency of manufacture is highly significant and advantageous particularly when economies of scale are considered.
The improvement in synthesis efficiency observed using Method 2 could be attributed to a reduction in steric hindrance due to absence of the large branched peptide structure when the lipid is added. A similar observation has been reported for the synthesis of a large branched and cyclic peptide from the Fc region of IgG Fc used as an immunomodulatory ligand for FcγRI where reduced yields were explained by steric hindrance caused by the presence of the branched peptide and can be overcome if its addition is preceded by cyclization of the linear portion of the peptide (Sheridan et al. 1999) .
A second advantage of Method 2 is in the use of DdeLys(Fmoc)-OH instead of Fmoc-Lys(Mtt)-OH used in Method 1; it takes much less time to remove the Dde protecting group than it takes to remove the Mtt protecting group. Two 5-min washes with 2% hydrazine in DMF is sufficient to remove Dde (Bycroft et al. 1993) , whereas continual washing with 1% TFA in DCM every 5 min for 1 h is required to remove Mtt. In addition, exposure of the peptidyl resin to DCM can result in loss of synthesis product during de-protection due to partial cleavage from the resin (Bourel et al. 2000) , a factor which may account for the lower yields of R 4 Pam 2 Cys obtained using Method 1. Finally, the efficiency of removal of the Mtt protecting group can be affected by the amino acid sequence flanking this residue (Bourel et al. 2000) . It is clear that use of Method 2 could save considerable manufacturing time and also decrease solvent consumption almost certainly reducing production costs. Importantly, the similarity in antigen-binding profiles as well as the in vitro and in vivo biological activity of R 4 Pam 2 Cys produced by Method 2 indicates adoption of Method 2 for manufacturing purposes. Similarities in biological activities were observed between R 4 Pam 2 Cys containing either d-isomers or l-isomers of lysine and arginine although there appeared to be a propensity for the d-isomer-containing compound to elicit fewer CD8 + T cells and slightly lower titers of antibody. Although these differences were not statistically significant and therefore in general agreement with a previous report (Makimura et al. 2006 ) in which l-and d-isomers of TLR2 ligand-containing immunogens were compared, these authors did not examine the biological activity of their TLR2 agonists as they related to the induction of antibody or CD8 + T cells when used in the context of an antigen adjuvant. These results therefore lead us to speculate that d-isomers of amino acids may affect antigen processing and presentation pathways involved in the generation of immune responses at least when initiated via processes mediated by TLR2 recognition and signalling. We also found that unlike Pam 2 CysSK 4 , which contains a linear tetra-lysine sequence, the d-and l-isomers of R 4 Pam 2 Cys are stable to the actions of trypsin. Although it has been reported that substituting l-amino acid residues of a linear peptide with their d-amino forms increases resistance against trypsin (Hamamoto et al. 2002; Tugyi et al. 2005) , our results and those of others demonstrate that a peptide with a branched arrangement is resistant to protease activity (Tam et al. 2002; Bracci et al. 2002) and more stable under physiological conditions (Tam et al. 2002; Dewan et al. 2009 ).
Although trypsin is a protease predominantly found in the digestive system of many vertebrates and our compounds are not delivered orally, we note, however, that the presence and activity of trypsin and trypsin-like proteases in other tissues including the brain (Wang et al. 2008) , muscle (Bossola et al. 2008 ), blood (Lefkowitz et al. 2010 ) and interstitial fluids (Xie et al. 2016) have also been reported in many studies. Together with its ability to specifically cleave the type of peptide bonds found in our lipopeptides, we therefore believe that its use in our experiments bears physiological relevance and demonstrates that these design features overcome some of the issues that limit the clinical use of peptide-based therapeutic agents (Liu and Nussenzweig 2010) .
Alum has been widely used in human vaccines for decades and has an excellent safety profile and efficacy record when long-lasting Th2 type antibody responses are sought (Lindblad 2004; Reed et al. 2009 ). The inability of alum to induce Th1 type cell responses or cytotoxic T cell responses, however, restricts its use in cases where cellular-mediated responses are needed (Gupta 1998) . Moreover, complete Freund's adjuvant has no translational application for use in D were incubated either alone or with trypsin (60 µg) for 10 min at 37 °C and then centrifuged at 13,000 rpm for 1 min and analyzed by RP-HPLC (RP-HPLC). The chromatograms were developed using 0.1% trifluoroacetic acid (TFA) in ddH 2 O and 0.1% TFA in acetonitrile as the limit solvent at a flow rate of 1 mL/min. Eluting material was detected by measuring the optical absorbance at 214 nm. Species within the dashed boxes were analyzed by mass spectrometry human vaccines as it is far too reactogenic and is prohibited from use in non-experimental animals (Stills 2005) .
In this study, we found that the antibody titers elicited using R 4 Pam 2 Cys to be comparable if not better than alum in some animals but less effective than CFA at inducing antibody. The heightened antibody response in CFA-treated animals may be attributed to the presence of higher levels of IgM-isotype antibodies which, although known to exhibit low antigen-binding affinities (Boes 2000) , bind to more antigenic sites by virtue of their pentavalent structure which explains the higher binding avidities observed (Muthana et al. 2015) . Nonetheless, all adjuvanted formulations were able to facilitate classswitching to IgG and in this context, R 4 Pam 2 Cys was the most effective at promoting isotype switching.
Taken altogether and given the ability of R 4 Pam 2 Cys to induce CD8 + T cell responses in animal models, this adjuvant appears to be more effective than alum (Chua et al. 2014 ) and also exhibits a better safety profile than CFA. Our findings also highlight the benefit of using R 4 Pam 2 Cys as a single adjuvant to achieve balanced Th1-and Th2-type immune responses that can be usually achieved through combined use of TLR5 and TLR9 agonists (Bargieri et al. 2008) or TLR4 and TL7 agonists (Goff et al. 2015) .
